Society

Creating value for a healthy society and creating innovation are key management issues that support Sysmex’s sustainable growth and the creation of social and economic value.
Providing products and services that contribute to disease prevention and improved prognosis, enhancing the productivity of healthcare professionals through the use of AI and automation technologies, and improving the economic efficiency of healthcare and access to healthcare represent important opportunities. These initiatives lead to enhanced corporate value by creating new business opportunities, expanding markets, and strengthening competitiveness. Furthermore, the appropriate protection of intellectual property rights and the utilization of advanced technologies, including AI, contribute to enhancingcorporate value by establishing a competitive advantage, improving productivity, and creating new business opportunities.
Meanwhile, risks such as failure to secure intellectual property rights or infringement of Sysmex’s intellectual propertyrights by third parties, the circulation of counterfeit products, and delays in utilizing advanced technologies, including AI, or responding to technological innovations may reduce competitiveness, result in lost business opportunities and lower sales,and ultimately impair corporate value.
Sysmex contributes to improving people’s health, reducing the burden on patients, and extending healthy life expectancyby providing test results that support early diagnosis and appropriate medical care. Additionally, by improving access to healthcare and alleviating the burden on healthcare professionals, we enhance the quality and efficiency of healthcare,contributing to the realization of a fulfilling and healthy society.

Sysmex aims to contribute to improving each individual’s quality of life (QOL) and extending healthy life expectancy by creating value for a healthy society and driving innovation.
Under our Mid-Term Plan, we will accelerate medical digital transformation (DX) through the use of testing data and AI while expanding the application of these initiatives to diagnostic support, personalized medicine, and preventive healthcare. Through these initiatives, we are enhancing the value provided by screening tests and expanding their application areas. Furthermore, by providing products, services, and solutions that leverage automation and digital technologies, we will contribute to improving the productivity of healthcare professionals, enhancing access to healthcare, and improving the economic efficiency of healthcare.
In addition, we aim to establish a sustainable competitive advantage and create social and economic value by promoting the acquisition and practical application of new technologies, expanding testing parameters, and creating, protecting, and leveraging intellectual property.

The Global Strategy Committee, which consists of the chairperson, the president, and the executive officers in charge, discusses and deliberates on the Group’s medium- to long-term management direction, as well as key strategies and challenges. Furthermore, the Business/ Technology Strategy Committee promotes innovation by aligning business and technology strategies. In addition, risks related to this topic are evaluated and managed under the company-wide risk management framework.

Sysmex aims to balance the enhancement of healthcare value with sustainable business growth by creating value for a healthy society and driving innovation. Under our Mid-Term Plan, we have identified enhancing the value of our screening test portfolio; promoting medical DX through the use of testing data and AI; implementing new technologies and creating new value as key initiatives, and we have established indicators to measure their progress.

Key indicators

For other indicators and targets, please refer to “Creating Value for a Healthy Society / Creating Innovation” under Sustainability Targets.(PDF:459KB)

The provision of responsible products, services, and solutions is a key management issue that supports Sysmex’s sustainable growth and value creation.
Supply chain disruptions caused by natural disasters, infectious diseases, geopolitical risks, or inadequate supplier management, as well as insufficient responses to increasingly complex regulatory approval requirements and product safety demands, or delays in adapting to changes in laws, regulations, and healthcare policies, may disrupt stable supply, reduce quality and trust, and result in lost business opportunities, posing risks that could impair corporate value.
Furthermore, enhancing quality and safety, responding appropriately to regulations in each country, expanding business in response to healthcare needs and institutional changes, and strengthening supply chain resilience represent opportunities to enhance corporate value by increasing trust, securing competitive advantages, and creating new business opportunities.
In terms of social impact, quality defects or inadequate customer care could lead to delays or errors in clinical care and testing at medical institutions, potentially resulting in negative impacts on customers and patients. Meanwhile, providing products, services, and solutions that appropriately address healthcare policies and medical needs in each country supports the execution of proper testing and diagnosis at medical institutions, contributing to the provision of appropriate medical care to patients.

Sysmex promotes the provision of responsible products, services, and solutions by pursuing quality and trust, maintaining a stable supply, and appropriately responding to healthcare policies and regulatory requirements in each country.
To maintain a stable supply, we are advancing reforms in the diagnostic reagent value chain. Through the optimization of production and procurement systems, the in-house production and substitution of critical raw materials, and the enhancement of quality management systems, we aim to enhance supply chain resilience and improve profitability.
We are also pursuing continuous improvements in quality and safety by reinforcing global quality management, enhancing post-market quality management, and leveraging digital technologies.
Furthermore, we continuously monitor healthcare policies, laws, regulations, and regulatory trends in each country. By fostering collaboration among global regulatory affairs and business divisions and regional group companies, we reflect institutional changes in our product strategies and business plans to respond swiftly and appropriately to changes in the market environment.
Through these initiatives, we aim to achieve both value creation for patients and sustainable business growth by providing a stable supply of high-quality products and services to medical settings.

To drive improvements in quality and safety, maintain a stable supply, and appropriately respond to regulations in each country, Sysmex has established key indicators for quality management and regulatory affairs activities, striving for continuous improvement.

Key indicators:

For other indicators and targets, please refer to “Providing responsible products, services, and solutions” under Sustainability Targets.(PDF:459KB)

Human capital is a crucial management foundation that supports Sysmex’s sustainable growth and value creation. Talent management challenges, such as intensifying competition for talent and the acquisition and development of highly specialized professionals, next-generation leaders, and diverse talent may lead to talent shortages and lower productivity, posing risks that could undermine competitiveness and impair corporate value.
Meanwhile, creating an environment where diverse talent can fully demonstrate their abilities and promoting talent development can improve employee engagement and foster innovation, thereby providing opportunities to strengthen our competitive advantage and enhance corporate value.
In terms of social impact, by providing growth opportunities for employees, improving job satisfaction, and offering workplace environments where diverse talent can thrive, we contribute to realizing a society where every individual can fully demonstrate their abilities.

At Sysmex, based on our Global HR Policy as a fundamental guideline, we promote the acquisition, development, and retention of diverse and outstanding talent. Guided by the concept of the employee journey,¹ we provide consistent support, from recruitment and career development to opportunities for autonomous learning and growth. At the same time, through our job-based personnel system, we promote talent management linked to our business strategy.
In addition, through the promotion of DE&I, we create a workplace environment where diverse talent can fully demonstrate their abilities with equal opportunities. Through these efforts, we aim to foster innovation by leveraging diverse perspectives and strengthen organizational capabilities.
Furthermore, based on the “Sysmex Declaration of a Healthy Company” and “Health Management Strategy Map,” we promote employee health improvement, well-being enhancement, and the creation of a safe and comfortable workplace environment. Through these initiatives, we seek to enhance employee engagement, foster innovation, and improve productivity, thereby contributing to the sustainable enhancement of corporate value.

Within the corporate management domain overseen by the Senior Managing Executive Officer, Sysmex has established functions responsible for diversity promotion and human resources development, driving efforts to maximize human capital. In addition, risks related to this topic are evaluated and managed under the company-wide risk management framework.

Positioning the maximization of human capital as a key management issue, we have established indicators and targets related to talent acquisition, development, and empowerment, as well as DE&I, health promotion, and occupational safety. By continuously tracking progress against each indicator, we enhance organizational capabilities, improve productivity, and enhance corporate value.

Key indicators:

For other indicators and targets, please refer to “Maximizing human capital” under Sustainability Targets.(PDF:459KB)